Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue growth of 68% YoY, with consumables up 79%. Gross margin improved to 61.5%. The company raised full-year guidance and announced partnerships with U.K. Biobank and GSK, totaling over 140,000 samples. ALMR added 35 publications, bringing the total to over 200, and strengthened its leadership team.

Original reporting
Published Nov 4, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ALMRBullishMed
01

Why it matters

The guidance raise and high‑margin performance provide a catalyst for short‑term price appreciation, while the large study contracts signal longer‑term revenue runway.

02

Market read

Earnings beat and guidance lift are the primary drivers of market reaction for ALMR.

03

What to watch

Execution risk of large‑scale studies and potential competition from other proteomics platforms.

Relevance 7/10Novelty 8/10Timing: post‑earnings today

Background

Alamar Biosciences reported Q3 2026 results, highlighting rapid revenue growth, margin expansion, and new partnerships with GSK and UK Biobank.

Company-level read

Ticker impact

$ALMRBullishHigh confidence
Context

Q3 2026 earnings call disclosed 68% revenue growth YoY and raised full-year revenue guidance.

Expected impact

likely upside as investors price in higher revenue outlook

Evidence & confidence

Earnings beat and guidance lift are fresh, material information for a small‑cap biotech.

Market effects

Strong results may boost sentiment in the proteomics and biotech sector.

Primarily U.S. biotech investors; limited broader market effect.

Modest, as Alamar is a niche player in low‑abundance protein detection.

Counterpoint

If the partnership deals fail to translate into revenue, the guidance may be overly optimistic.

Key entities

  • Alamar Biosciences

    US‑listed biotech developing the NULISA proteomics platform.

  • GSK

    Biopharma partner for a 60,000‑sample biomarker study.

  • UK Biobank

    Collaborator on an 80,000‑sample neurodegeneration study.

Related articles

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with gross margin at 61.5%. Net loss was $13.3M. Full-year revenue guidance raised to $121M-$123M. Company finalized large-scale studies with UK Biobank and GSK, focusing on neurodegenerative and inflammatory diseases. Cash position at $231.5M supports expansion plans. President Todd White to retire by year-end.

$ALMRMed

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o

$ALMRLow

Alamar Biosciences' Protein Signature Detects ALS With 98.3% Accuracy In Study

Alamar Biosciences (ALMR) reported that Emory University researchers used its NULISA tech to identify a 10-protein blood signature with 98.3% accuracy in detecting ALS. The study, published in Nature Communications, involved 632 ALS patients and 160 healthy controls for development, and 144 ALS patients and 37 healthy controls for validation. The signature outperformed the established NFL biomarker. ALMR's stock closed at $34.30, up 7.42%, and was at $34.15 in overnight trading.